Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, has appointed Jim Wang, Ph.D., senior vice president, head of regulatory affairs. Reporting directly to Laurent Fischer, M.D., Adverum’s president and chief executive officer, Dr. Wang will lead regulatory strategies and execution for the company’s product pipeline.

Dr. Wang joins Adverum from PTC Therapeutics, where he served as vice president, global head of regulatory strategy, leading the planning and execution of worldwide regulatory activities across all therapeutic areas focusing on rare disease. He also provided oversight to a cross-functional team for the marketing application of the gene therapy product eladocagene exuparvovec. Previously, he worked with Spark Therapeutics, serving as vice president, head of regulatory affairs strategy.

Dr. Wang earned his Ph.D. in chemistry from the University of Illinois at Urbana-Champaign and an MBA from Pennsylvania State University.

See Full Press Release Here